New Drugs from Bristol-Myers

Bristol-Myers has 60 potential drugs in its pipeline.
The AP (3/5, Johnson) reports, "Executives at Bristol-Myers Squibb Co. told analysts Thursday at a business briefing that the drugmaker has 60 potential drugs in development, seven in late-stage studies." Bristol-Myers "said it expects future revenue from those medicines and growing sales from existing drugs to help offset an expected plunge in Plavix sales in 2012." The AP adds that key drugs in development "include the blood thinner apixaban, organ transplant drug belatacept, cancer drug brivanib, diabetes drug dapagliflozin and skin cancer drug ipilimumab."